Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 284-292

  Saito, Tsuyoshi ^a   Takehara, Masaki ^a   Tanaka, Ryoichi ^a   Lee, Rong ^a   Horie, Miyabi ^a   Wataba, Koya ^a   Ito, Eiki ^a   Kudo, Ryuichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ANTINEOPLASTIC AGENT; CASPASE; CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; MITOMYCIN; MITOMYCIN C; PROTEIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG RESPONSE; ENZYME ACTIVATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SAMPLE; TUMOR; UTERINE CERVIX CARCINOMA; UTERINE CERVIX TUMOR;

EID: 0742324872     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.09.027     Document Type: Article

References (54)

1. Buckley C., Fox H. Pathology of clinical invasive carcinoma of cervix. 1992;Churchill Livingstone, Edinburgh.
2. Weiss R.J., Lucas W.E. Adenocarcinoma of the uterine cervix. Cancer. 57:1986;1996-2001.
3. Berek J.S., Hacker N.F., Fu Y.S., Sokale J.R., Leuchter R.C., Lagasse L.D. Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Obstet. Gynecol. 65:1985;46-52.
4. Moberg P.J., Einhorn N., Silfversward C., Soderberg G. Adenocarcinoma of the uterine cervix. Cancer. 57:1986;407-410.
5. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
6. Takehara M., Hayakawa O., Saito T.et al. Combination chemotherapy with cisplatin, aclacinomycin A, and mytomycin C for primary, advanced, or recurrent cervical adenocarcinoma. J. Gynecol. Technol. 5:1999;151-155.
7. Zanetta G., Lissoni A., Gabriele A.et al. Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma. Gynecol. Oncol. 64:1997;431-435.
8. Iwasaka T., Fukuda K., Hara K.et al. Neoadjuvant chemotherapy with mitomycin C, etoposide, and cisplatin for adenocarcinoma of the cervix. Gynecol. Oncol. 70:1998;236-240.
9. Benedetti-Panici P., Maneschi F., Cutillo G.et al. Modified type IV-V radical hysterectomy with systematic pelvic and aortic lymphadenectomy in the treatment of patients with stage III cervical carcinoma. Feasibility, technique, and clinical results. Cancer. 78:1996;2359-2365.
10. Scarabelli C., Zarrelli A., Gallo A., Visentin M.C. Multimodal treatment with neoadjuvant intraarterial chemotherapy and radical surgery in patients with stage IIIB-IVA cervical cancer. A preliminary study. Cancer. 76:1995;1019-1026.
11. Shaw P., Bovey R., Tardy S., Sahli R., Sordat B., Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. U. S. A. 89:1992;4495-4499.
12. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
13. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124:1994;1-6.
14. Lowe S.W., Bodis S., McClatchey A.et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
15. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:1994;2013-2026.
16. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:1994;2287-2291.
17. Takahashi T., D'Amico D., Chiba I., Buchhagen D.L., Minna J.D. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J. Clin. Invest. 86:1990;363-369.
18. Yamaguchi A., Nakagawara G., Kurosaka Y., Nishimura G., Yonemura Y., Miyazaki I. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br. J. Cancer. 68:1993;399-402.
19. Elledge R.M., Allred D.C. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res. Treat. 52:1998;79-98.
20. Fisher C.J., Gillett C.E., Vojtesek B., Barnes D.M., Millis R.R. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br. J. Cancer. 69:1994;26-31.
21. el-Deiry W.S., Harper J.W., O'Connor P.M.et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
22. Miyashita T., Reed J.C. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:1992;5407-5411.
23. Porter A.G., Janicke R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:1999;99-104.
24. Creasman W.T. New gynecologic cancer staging. Gynecol. Oncol. 58:1995;157-158.
25. Saito T., Schlegel R., Andresson T., Yuge L., Yamamoto M., Yamasaki H. Induction of cell transformation by mutated 16K vacuolar H+-atpase (ductin) is accompanied by down-regulation of gap junctional intercellular communication and translocation of connexin 43 in NIH3T3 cells. Oncogene. 17:1998;1673-1680.
26. Lu X., Toki T., Konishi I., Nikaido T., Fujii S. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer. 82:1998;2409-2417.
27. Costa S., Terzano P., Santini D.et al. Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome. Am. J. Clin. Pathol. 116:2001;729-737.
28. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88:1996;1442-1455.
29. Lorincz A.T., Temple G.F., Kurman R.J., Jenson A.B., Lancaster W.D. Oncogenic association of specific human papillomavirus types with cervical neoplasia. J. Natl. Cancer Inst. 79:1987;671-677.
30. Matsuo N., Iwasaka T., Hayashi Y., Hara K., Mvula M., Sugimori H. Polymerase chain reaction analysis of human papillomavirus in adenocarcinoma and adenosquamous carcinoma of the uterine cervix. Int. J. Gynaecol. Obstet. 41:1993;251-256.
31. Duggan M.A., Benoit J.L., McGregor S.E., Nation J.G., Inoue M., Stuart G.C. The human papillomavirus status of 114 endocervical adenocarcinoma cases by dot blot hybridization. Human Pathol. 24:1993;121-125.
32. Leminen A., Paavonen J., Vesterinen E., Wahlstrom T., Rantala I., Lehtinen M. Human papillomavirus types 16 and 18 in adenocarcinoma of the uterine cervix. Am. J. Clin. Pathol. 95:1991;647-652.
33. Scheffner M., Munger K., Byrne J.C., Howley P.M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5523-5527.
34. Uchiyama M., Iwasaka T., Matsuo N., Hachisuga T., Mori M., Sugimori H. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix. Gynecol. Oncol. 65:1997;23-29.
35. Bottini A., Berruti A., Bersiga A.et al. p53 but not Bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin. Cancer Res. 6:2000;2751-2758.
36. Reles A., Wen W.H., Schmider A.et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 7:2001;2984-2997.
37. Garzetti G.G., Ciavattini A., Provinciali M.et al. Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. Anticancer Res. 16:1996;3229-3234.
38. Sultana H., Kigawa J., Kanamori Y.et al. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann. Oncol. 14:2003;214-219.
39. Ogawa M., Maeda K., Onoda N., Chung Y.S., Sowa M. Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br. J. Cancer. 75:1997;1617-1620.
40. Levesque M.A., Katsaros D., Massobrio M.et al. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clin. Cancer Res. 6:2000;3260-3270.
41. Werness B.A., Jobe J.S., DiCioccio R.A., Piver M.S. Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int. J. Gynecol. Pathol. 16:1997;149-155.
42. Wakasugi E., Kobayashi T., Tamaki Y.et al. p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am. J. Clin. Pathol. 107:1997;684-691.
43. Geisler H.E., Geisler J.P., Miller G.A.et al. p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer. 92:2001;781-786.
44. Silvestrini R., Veneroni S., Daidone M.G.et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 86:1994;499-504.
45. Gasparini G., Barbareschi M., Doglioni C.et al. Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. 1:1995;189-198.
46. Sinicrope F.A., Hart J., Hsu H.A., Lemoine M., Michelassi F., Stephens L.C. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin. Cancer Res. 5:1999;1793-1804.
47. Sjostrom J., Blomqvist C., von Boguslawski K.et al. The predictive value of Bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 8:2002;811-816.
48. van Slooten H.J., van de Vijver M.J., van de Velde C.J., van Dierendonck J.H. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br. J. Cancer. 77:1998;789-796.
49. Ohkouchi T., Sakuragi N., Watari H.et al. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am. J. Obstet. Gynecol. 187:2002;353-359.
50. Kupryjanczyk J., Szymanska T., Madry R.et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br. J. Cancer. 88:2003;848-854.
51. Henriksen R., Wilander E., Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br. J. Cancer. 72:1995;1324-1329.
52. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
53. Cryns V., Yuan J. Proteases to die for. Genes Dev. 12:1998;1551-1570.
54. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 15:2001;2922-2933.